Abstract: Described are personal care compositions, comprising an aqueous dispersion comprising an ethylene acrylic acid copolymer and a least one cosmetically acceptable surfactant, emollient, or cosmetic active.

Abstract: Aqueous hair care compositions which provide hair styling, hair lightening and hair conditioning benefits are disclosed. The compositions provide hair lightening effects greater than that which would typically be achieved using hydrogen peroxide solutions alone. The compositions comprise a stabilized oxidative compound, a film-forming hair care polymer, a cationic hair care polymer, and water. The method of conditioning, styling and coloring hair utilizing the disclosed compositions is also disclosed.

Abstract: A tissue product comprising an additive composition onto at least the surface of a fibrous article in order to increase the surface potential of the article, while retaining or improving manufacturing efficiency is disclosed. The additive composition comprises a bacteriostatic component and more preferably a water-soluble adhesive component and a bacteriostatic component. In some aspects, the additive may also contain additional water-soluble modifier components. Tissue products according to the present disclosure can attract and trap negatively charged matter, such as bacteria, into the tissue web. As such, tissue products can pickup bacteria from a surface and substantially hold the bacteria in the sheet to help prevent spreading bacteria to other surfaces.

Abstract: A camptothecin/polymer dual phase drug release system is described that is stable in both liquid and lyophilized states. The polymer contains acetals and/or ketals.

Abstract: Skin care compositions comprising certain substituted diamines, which are particularly beneficial for skin lightening and achieving evenness of color, especially for face and underarm skin.

Abstract: The present invention concerns topical sun-protecting formulations including therapeutically effective amounts of Vitamin D, including formulations that provide Vitamin D in bioavailable amounts that correspond to decreased natural Vitamin D production resulting from the sun-blocking effects of the formulations and formulations for the prevention and treatment of disorders and disease states associated with vitamin D deficiency and vitamin D insufficiency.

Abstract: The biocompatible, biodegradable materials in the solid and/or liquid form are based on segmented linear polyurethanes and/or segmented crosslinked polyurethanes based on A) one or more biocompatible polyols susceptible to hydrolytic and/or enzymatic degradation having a molecular weight of 100 to 20,000 dalton and a number of active hydroxyl groups per molecule (functionality) of at least two or higher; B) one or more diisocyanates and/or triisocyanates; and C) one or more low molecular weight chain extenders having a molecular weight of 18 to 1000 dalton and the functionality of at least two or higher.

Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.

Abstract: Silver nanoparticles associated with 20 to 80% by weight of a biocomponent of the genus Lactobacillus, said silver nanoparticles having a ratio of the average particle size to the specific surface area (BET) of from 0.015 to 0.

Abstract: The invention pertains to a new method for formulating pharmaceutical active ingredients in such a way as to protect them when ingested orally, and to allow for the controlling of the release of the active ingredient in the intestine. It relies upon the use of thickening acrylic emulsions with a pH greater than 5, containing hydrophobic groups, in order to encapsulate the pharmaceutical active ingredients for the purpose of encouraging their passage through the gastrointestinal barrier, while controlling the release kinetics of said active ingredients.

Abstract: A solubilizing composition containing (A) at least one oily component selected from esters of oleic acid with alcohols having 1 to 3 carbon atoms and triglycerides of fatty acids having 6 to 12 carbon atoms, (B) a polyoxyethylenesorbitan fatty acid ester, (C) a polyhydric alcohol which is liquid between 15° C. and 25° C., and (D) one or more acidic phospholipids where the fatty acid constituting an acyl group thereof is selected from saturated fatty acids having 6 to 14 carbon atoms and unsaturated fatty acids having 16 to 18 carbon atoms, which contains 20 to 40% by weight of the component (A), 30 to 45% by weight of the component (B), 15 to 40% by weight of the component (C), and 0.5 to 4% by weight of the component (D), based on 100% by weight of a total amount of the components (A) to (D).

Abstract: A microparticle includes an agglomerate of a hydrophilic active substance containing particle, which particle includes an amphiphilic polymer composed of a hydrophobic segment of poly(hydroxy acid) and a hydrophilic segment of polysaccharides or polyethylene glycol, and a hydrophilic active substance. It is characterized by an efficient inclusion of the hydrophilic active substance, and a release of the hydrophilic active substance at an appropriate speed in the human body, and is hence very useful as a DDS pharmaceutical preparation.

Abstract: Use of the one or more oligomers of lactic acid with the following formula (I) wherein n is an integer from 2 to 25 such as, e.g., from 2 to 20, from 3 to 25, from 3 to 20, from 2 to 15, from 3 to 15, from 2 to 10, from 3 to 10, from 4 to 10, or from 4 to 9 or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefit of an acidic environment especially a gynaecological infection such as a bacterial infection, such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (Candida albicans), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).

Abstract: Provided are an organopolysiloxane that exhibits good dispersion stability within not only organic oil agents but also cosmetic materials that contain a powder, and is able to produce a cosmetic material that exhibits excellent skin affinity, an organopolysiloxane that does not impart a sticky feeling, and exhibits excellent skin affinity and skin adhesion, and a cosmetic material including such an organopolysiloxane. The organopolysiloxane is represented by formula (1) below: in which R1 represents a hydrocarbon group such as an alkyl group, R2 represents a group represented by formula (3) or formula (4) below: in which either R4 represents a specific hydrocarbon group and R5 represents a hydrogen atom or a specific hydrocarbon group, or alternatively, at least one of R4 and R5 represents a hydroxyalkyl group, and A represents a group containing an organosilyl group or organosiloxane residue.

Abstract: The invention provides active agents, such as paclitaxel, rapamycin, or 17-AAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-AAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity. It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations.

Abstract: The present invention relates to an improved nitrification inhibitor composition and its use in agricultural applications.

Abstract: This invention relates to thermoplastic elastomers comprising at least one silicone ionomer. These thermoplastic elastomers may be reprocessed and/or recycled.

Abstract: A method for forming an extracellular matrix material (ECM) material includes providing at least an ECM composition containing ECM particles varying in their capacity for migration through a fluid medium, including at least one population of expanded ECM particles. The ECM composition is combined in a fluid medium to form a flowable ECM composition. The flowable ECM composition is subjected to a centrifugal force in a mold for a period of time sufficient to distribute the ECM particles according to differences in their physical characteristics. The ECM composition is dried to form a dried ECM material having a density gradient extending from a less dense region to a more dense region. The dried ECM material may formed as a porous, substantially acellular ECM material expandable in an aqueous fluid environment by at least 100% in volume.

Abstract: In one aspect, the present invention features a process for making a tablet including a pharmaceutically active agent wherein the tablet has both an immediate release region and a modified release region. The method includes the steps of: (a) forming a tablet shape including a powder blend containing a pharmaceutically active agent and a thermally-sensitive material; and (b) applying energy in different amounts to different regions of the tablet shape to form the tablet in a manner such that: (i) a first region of the tablet shape is exposed to said energy for a sufficient period of time to melt the thermally-sensitive material within the first region to form said modified release region of said tablet; and (ii) a second region of said tablet shape is not so exposed to the energy such that said second region forms the immediate release region of said tablet.

Abstract: New triflusal-containing polymeric compounds resulting from the polymerization of 2-(methacryloyloxy)ethyl 2-acetyloxy-4-(trifluoromethyl)benzoate with butyl acrylate are described. These new polymers exhibit good adhesion and crack-bridging properties and are particularly suitable for the coating of stents.